Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.


Updates from The Motley Fool

Latest updates on Gilead Sciences from Fool.com.  The Fool has written over 1200 articles on Gilead Sciences.
3 Dividend Stocks to Buy on Sale

Corning, Wells Fargo, and Gilead Sciences pay great dividends -- and all three stocks are bargains.

3 History-Making Stocks

These companies have each done something special, for better or worse.



Stock Performance

View Interactive GILD Charts
Sponsored by

Key Data Points

Primary metrics and data points about Gilead Sciences.
Current Price: $71.80
Prev Close: $70.65
Open: $70.97
Bid: $71.75
Ask: $71.76
Day's Range: $70.83 - $71.85
52wk Range: $63.76 - $88.85
Volume: 5,085,547
Avg Vol 9,494,142
Market Cap: $94B
P/E (ttm): 7.47
EPS (ttm): $9.46
Div & Yield: $2.08 (2.9%)

Company Rating

What our community thinks about Gilead Sciences.
CAPS Rating 5 out of 5
 
3636 Outperform
86 Underperform
CAPS All Stars
 
796 Outperform
16 Underperform

How do you think Gilead Sciences will perform against the market?



You pick for Gilead Sciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John Milligan, CEO

82% Approve

Based on 52 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Gilead Sciences.

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers